|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 单重和多重调谐质量惯容阻尼器控制连体超高层建筑风振响应比较研究显示文摘连体超高层建筑因存在强烈的气动干扰,在强风下可能会出现大幅相对振动,调谐质量惯容阻尼器(TMDI)是一种振动控制装置,其惯容器两端的相对加速度较大时,TMDI振动控制效果较好。结合两者各自的特点提出了多重调谐质量惯容阻尼器(MTMDI)控制连体超高层建筑的风振响应,两个TMDI分别控制两栋建筑各自的一阶自振频率。首先建立了MTMDI控制连体超高层建筑风致响应数学模型,然后开展了某连体超高层建筑的刚性模型同步测压风洞试验;最后,基于该数学模型和测压风洞试验结果分析了该连体建筑在分别安装两个和单个TMDI对风振加速度和位移响应的减振效果。研究结果表明:虽然两个TMDI的总质量和总惯容量比单个TMDI相应的参数小,但两者的减振效果基本相同,两者都能有效地减小两栋建筑在各个风向角下的加速度响应,如在270°风向角下,安装TMDI后两栋建筑顶层加速度响应分别减小了37.5%和50.0%;对于位移响应,两者都可以减小高栋建筑的响应,其对低栋建筑在少部分风向角下的减振效果并不理想。 | 王钦华 雷伟 祝志文 TIWARI Nayan Deep | 2021 | 建筑结构学报2021，42，4： | 10 |
| 2 | Sarcopenia in Chronic Liver Disease:A Metabolic Perspective显示文摘Sarcopenia,a condition of low muscle mass,quality,and strength,is commonly found in patients with chronic liver disease(CLD)and is associated with adverse clinical out-comes including reduction in quality of life,increased mor-tality,and complications.A major contributor to sarcopenia in CLD is the imbalance in muscle protein turnover wherein changes in various metabolic factors such as hyperammone-mia,amino acid deprivation,hormonal imbalance,gut dys-biosis,insulin resistance,chronic inflammation,etc.have important roles.In particular,hyperammonemia is a key mediator of the liver-gut axis and is known to contribute to sarcopenia by various mechanisms including increased ex-pression of myostatin,increased phosphorylation of eukary-otic initiation factor 2a,cataplerosis ofα-ketoglutarate,mi-tochondrial dysfunction,increased reactive oxygen species that decrease protein synthesis and increased autophagy-mediated proteolysis.Skeletal muscle is a major organ of insulin-induced glucose metabolism,and sarcopenia is closely linked to insulin resistance and metabolic syndrome.Patients with liver cirrhosis are in a hypermetabolic state that is associated with catabolism and depletion of amino acids,particularly branched-chain amino acids.Sarcopenia can have significant implications for nonalcoholic fatty liver disease,the most common form of CLD worldwide,because of the close link between metabolic syndrome and sarcope-nia.This review discusses the potential metabolic derange-ment as a cause or effect of sarcopenia in CLD,as well as interorgan crosstalk,which that might help identifying a novel therapeutic strategies. | Ramesh Kumar Sabbu Surya Prakash Rajeev Nayan Priyadarshi Utpal Anand | 2022 | Journal of Clinical and Translational Hepatology2022，10，6： | 4 |
| 3 | Chronic renal dysfunction in cirrhosis:A new frontier in hepatology显示文摘Chronic kidney disease(CKD)in patients with liver cirrhosis has become a new frontier in hepatology.In recent years,a sharp increase in the diagnosis of CKD has been observed among patients with cirrhosis.The rising prevalence of risk factors,such as diabetes,hypertension and nonalcoholic fatty liver disease,appears to have contributed significantly to the high prevalence of CKD.Moreover,the diagnosis of CKD in cirrhosis is now based on a reduction in the estimated glomerular filtration rate of<60 mL/min over more than 3 mo.This definition has resulted in a better differentiation of CKD from acute kidney injury(AKI),leading to its greater recognition.It has also been noted that a significant proportion of AKI transforms into CKD in patients with decompensated cirrhosis.CKD in cirrhosis can be structural CKD due to kidney injury or functional CKD secondary to circulatory and neurohormonal imbalances.The available literature on combined cirrhosis-CKD is extremely limited,as most attempts to assess renal dysfunction in cirrhosis have so far concentrated on AKI.Due to problems related to glomerular filtration rate estimation in cirrhosis,the absence of reliable biomarkers of CKD and technical difficulties in performing renal biopsy in advanced cirrhosis,CKD in cirrhosis can present many challenges for clinicians.With combined hepatorenal dysfunctions,fluid mobilization becomes problematic,and there may be difficulties with drug tolerance,hemodialysis and decision-making regarding the need for liver vs simultaneous liver and kidney transplantation.This paper offers a thorough overview of the increasingly known CKD in patients with cirrhosis,with clinical consequences and difficulties occurring in the diagnosis and treatment of such patients. | Ramesh Kumar Rajeev Nayan Priyadarshi Utpal Anand | 2021 | World Journal of Gastroenterology2021，27，11： | 3 |
| 4 | Electro-magnetohydrodynamic Flow of Biofluid Induced by Peristaltic Wave: A Non-newtonian Model显示文摘 | Gopal Chandra Shit Nayan Kumar Ranjit Aniruddha Sinha | 2016 | Journal of Bionic Engineering2016，13，3： | 2 |
| 5 | Physician-level variation in the diagnosis of myocardial infarction and the use of angiography among veterans with elevated troponin显示文摘Background:Cardiac troponin assays have improved the ability to detect myocardial damage.However,ascertaining whether troponin elevation is due to myocardial infarction(MI) or secondary to another process can be challenging.Our aim is to evaluate provider-level variation in the diagnosis of MI and the use of invasive coronary angiography(ICA) among patients with undifferentiated elevations in cardiac troponin.Methods:We analyzed data from all patients with elevated troponin levels in a single Veterans Affairs(VA) Medical Center between 2006 and 2007.One of several cardiologists prospectively evaluated each patient's presentation and course of care.We compared the frequency of MI diagnosis and ICA use between physicians using univariate odds ratios(OR).Results:Among 761 patients,34.0% were diagnosed with MI and 25.9% underwent ICA.The unadjusted rates of MI(23.9% to 56.7%,P=0.02) and ICA(17.3% to 73.3%,P<0.001) differed between physicians.Comparing the patient cohorts for each physician,baseline characteristics were similar except for chest pain.In multivariate regression,factors associated with the use of cardiac ICA included an abnormal electrocardiograph(ECG)(OR=1.89,P=0.014),level of troponin(OR=1.71,P=0.004),chest pain(OR=8.60,P<0.001),and care by non-VA physicians(OR=4.45,P=0.006).One physician had a lower ICA use(OR=0.56,P=0.017).In multivariate regression of MI,no physician-level variation was observed.Conclusion:Among patients with elevated troponin,the likelihood of being diagnosed with MI and undergoing ICA is dependent on their clinical presentation.After adjustment,physician-level variation in care was observed for the use of ICA,but not for the diagnosis of MI. | David E.Winchester Nayan Agarwal Lucas Burke Steven Bradley Tatiana Schember Carsten Schmalfuss | 2016 | Journal of Medical Colleges of PLA(China)2016，31，3： | 2 |
| 6 | Erythropoietin therapy after out-of-hospital cardiac arrest:A systematic review and meta-analysis显示文摘AIM To assess safety and efficacy of early erythropoietin(Epo) administration in patients with out-of-hospital cardiac arrest(OHCA).METHODS A systematic literature search was performed using PubM ed,MEDLINE,EMBASE,EBSCO,CINAHL,Web of Science and Cochrane databases,of all studies published from the inception through October 10,2016.Inclusion criteria included:(1) Adult humans with OHCA and successful sustained return of spontaneous circulation;and(2) studies including mortality/brain death,acute thrombotic events as their end points.Primary efficacyoutcome was 'brain death or Cerebral Performance Category(CPC) score of 5'.Secondary outcomes were 'CPC score 1,and 2-4','overall thrombotic events' and 'acute coronary stent thrombosis'.RESULTS We analyzed a total of 606 participants(n = 276 received Epo and n = 330 with standard of care alone) who experienced OHCA enrolled in 3 clinical trials.No significant difference was observed between the Epo and no Epo group in brain death or CPC score 5(OR = 0.77;95%CI:0.42-1.39),CPC score 1(OR = 1.16,95%CI:0.82-1.64),and CPC score 2-4(OR = 0.77,95%CI:0.44-1.36).Epo group was associated with increased thrombotic complications(OR = 2.41,95%CI:1.26-4.62) and acute coronary stent thrombosis(OR = 8.16,95%CI:1.39-47.99).No publication bias was observed.CONCLUSION Our study demonstrates no improvement in neurological outcomes and increased incidence of thrombotic events and acute coronary stent thrombosis in OHCA patients who were treated with Epo in addition to standard therapy. | Rahul Chaudhary Jalaj Garg Parasuram Krishnamoorthy Kevin Bliden Neeraj Shah Nayan Agarwal Rahul Gupta Abhishek Sharma Karl B Kern Nainesh C Patel Paul Gurbel | 2017 | World Journal of Cardiology2017，9，12： | 2 |
| 7 | Angiopoietin-1-expressing adipose stem cells genetically modified with baculovirus nanocomplex: investigation in rat heart with acute infarction显示文摘 | Satya Prakash Dominique Shum-Tim Afshan Afsar Khan Madhur Nayan Arghya Paul | 2012 | International Journal of Nanomedicine (default)2012，，： | 1 |
| 8 | Optimization of homogenizing mode for aluminum alloy AA7075 using calorimetric and microstructural studies显示文摘 | Niraj Nayan S. Y. S. Narayana Murty Gotvind M. C. Mittal P. P. Sinha | 2009 | Metal Science and Heat Treatment2009，，7： | 1 |
| 9 | Coronary Artery Chronic Total Occlusion显示文摘Coronary artery chronic total occlusion(CTO)is defi ned as an occluded coronary artery segment without anterograde fl ow for at least three months.It can be classified as a“true”or“functional”CTO based on flow characteristics.In“true”CTO,there is no anterograde flow.In“functional”CTO,there is minimal anterograde flow through the occluded segment of the coronary artery.CTO is a common fi nding during coronary angiography and its prevalence may vary depending on the reported literature.Among patients without previous coronary artery bypass grafting(CABG),CTO is found in about 20–30% of the patients.CTO may develop insidiously over a period of time and involve a complex interplay between intracellular and extracellular factors,smooth muscle and foam cells,calcifi cation,and neovascularization.There is a growing body of evidence to support that CTO revascularization may improve clinical outcome when compared to medical management.Both the European and American cardiovascular societies support CTO revascularization with a class 2a recommendation(level of evidence B).Historically,due to low procedural success rate,apparent ineffi cient resource utilization,potential increase in complication rates and uncertain clinical benefi ts,only about 10–20%of patients with CTO are treated with percutaneous coronary intervention(PCI).Recent advances using novel and innovative techniques with dedicated equipment have signifi cantly improved the procedural success rate for CTO PCI to about 90%in the hands of experienced operators.With increasing interest in CTO PCI coupled with increased educational effort,CTO PCI likely will become more accessible to patients in need of CTO revascularization.Ongoing advancement in innovative techniques and equipment will continue to improve procedural success rates and reduce procedural complication rate for CTO PCI.Furthermore,there are a number of prospective clinical trials on the horizon which should help defi ne the clinical benefi ts and limitations of CTO PCI in the near future. | Calvin Choi Nayan Agarwal Ki Park R.David Anderson | 2016 | Cardiovascular Innovations and Applications2016，，B05： | 1 |
| 10 | Development and characterization of Al–Li alloys显示文摘 | R.K. Gupta Niraj Nayan G. Nagasireesha S.C. Sharma | 2006 | Materials Science & Engineering A2006，，1： | 1 |
| 11 | Marrow stromal cells for cell-based therapy: the role of antiinflammatory cytokines in cellular cardiomyoplasty 显示文摘 | CHEN G NAYAN M DUONG M | 2010 | Ann Thorac Surg2010，90，1： | 1 |
| 12 | Superior therapeutic potential of young bone marrow mesenchymal stem cells by direct intramyocardial delivery in aged recipients with acute myocardial infarction:in vitro and in vivo investigation显示文摘 | Nayan M Paul A Chen G | 2011 | J Tissue Eng2011，2011，74： | 1 |
| 13 | YouTube: A good source of information on pediatric tonsillectomy?显示文摘 | Julie E. Strychowsky Smriti Nayan Forough Farrokhyar Jonathan MacLean | 2013 | International Journal of Pediatric Otorhinolaryngology2013，，6： | 1 |
| 14 | Development and characterization of Al-Li alloys显示文摘 | GUPTA R K NAYAN N NAGASIREESHA G | 2006 | Materials Science and Engineering A2006，420，： | 1 |
| 15 | Antioxidant activity of Indian propolis and its chemical constituents显示文摘 | Rajibul A L Ismail S Nayan R | 2010 | Food Chem2010，122，1： | 1 |
| 16 | Development and characterization of Al -Li alloys显示文摘 | Gupta R K Nayan N Sharma S C | | 0，，： | 1 |
| 17 | Association of COVID-19 with hepatic metabolic dysfunction显示文摘The coronavirus disease 2019(COVID-19)pandemic continues to be a global problem with over 438 million cases reported so far.Although it mostly affects the respiratory system,the involvement of extrapulmonary organs,including the liver,is not uncommon.Since the beginning of the pandemic,metabolic comorbidities,such as obesity,diabetes,hypertension,and dyslipidemia,have been identified as poor prognostic indicators.Subsequent metabolic and lipidomic studies have identified several metabolic dysfunctions in patients with COVID-19.The metabolic alterations appear to be linked to the course of the disease and inflammatory reaction in the body.The liver is an important organ with high metabolic activity,and a significant proportion of COVID-19 patients have metabolic comorbidities;thus,this factor could play a key role in orchestrating systemic metabolic changes during infection.Evidence suggests that metabolic dysregulation in COVID-19 has both short-and long-term metabolic implications.Furthermore,COVID-19 has adverse associations with metabolic-associated fatty liver disease.Due to the ensuing effects on the renin-angiotensin-aldosterone system and ammonia metabolism,COVID-19 can have significant implications in patients with advanced chronic liver disease.A thorough understanding of COVID-19-associated metabolic dysfunction could lead to the identification of important plasma biomarkers and novel treatment targets.In this review,we discuss the current understanding of metabolic dysfunction in COVID-19,focusing on the liver and exploring the underlying mechanistic pathogenesis and clinical implications. | Ramesh Kumar Vijay Kumar Rahul Arya Utpal Anand Rajeev Nayan Priyadarshi | 2022 | World Journal of Virology2022，11，5： | 1 |
| 18 | Development and charac-terization of Al-Li alloys显示文摘 | Gupta R K Nayan N Sharma S C | | 0，，： | 1 |
| 19 | Malignant Peripheral Nerve Sheath Tumor With Primitive Neuroepithelial Differentiation in an Adult:A Case Report显示文摘 | Arti Rameshrao Anvikar Medha Pradeep Kulkarni Nayan Anant Ramteerthakar | 2012 | International journal of surgical pathology2012，20，5： | 1 |
| 20 | Thymic cyst:a fourth branchial cleft anomaly显示文摘 | Nayan S MacLean J Sommer D | 2010 | Laryngoscope2010，120，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员